摘要
表皮生长因子受体(epidermal growth factor receptor,EGFR)在多种肿瘤中存在高表达,与肿瘤的进展、耐放化疗有关。抑制EGFR信号传导通路可控制肿瘤的发展。尼妥珠单抗作为一种新型的抗EGFR单克隆抗体,已应用于多种恶性肿瘤中。全文就尼妥珠单抗联合放疗在肿瘤治疗中的相关临床研究作一综述。
Epidermal growth factor receptor（EGFR） has overexpressed in many tumors,associating with tumor progression and resistances to radiation and chemotherapy. Inhibition of EGFR signaling pathway can control tumor development. Nimotuzumab is a new kind of EGFR monoclonal antibody, has been applied in a variety of malignant tumors. The relevant clinical researches about nimotuzumab combined radiotherapy are reviewed in this article.
出处
《中国肿瘤》
CAS
2014年第3期228-233,共6页
China Cancer
